Research & Development
Golden Biotechnology announces positive results for Antroquinonol phase two clinical study
27 November 2020 -

Golden Biotechnology Corporation (4132.TWO), a Taiwan-based biopharmaceutical company, has revealed that its Antroquinonol, a new drug intended to treat acute myeloid leukaemia (AML) patients, outperformed other listing drugs in its phase two clinical study conducted in Russia, it was reported on Thursday.

The result indicated higher remission rates and survival rates assuring fewer patients will require blood transfusions. The primary efficacy indicator results demonstrated the overall remission rate of patients with relapsed AML reaches 50%. 80% of patients' abnormal blasts counts in bone marrow or blood reduced to less than 5% after treatment. The secondary outcome measures resulted in the overall survival rate of patients with relapsed AML by 100% at the sixth month after the treatment. The trial was an open-label, non-randomised, Phase 2a study to assess efficacy and safety/tolerability profiles in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible

The new drug received orphan drug designation from the US FDA for the treatment of AML in 2015.

Login
Username:

Password: